Advanced FIGO III–IV Fallopian Tube Carcinoma in Women: Treatment After Primary Cytoreductive Surgery

Clinical scenario

This protocol addresses women with advanced (FIGO stage III or IV) fallopian tube carcinoma who have a high likelihood of achieving optimal surgical debulking and are without high perioperative risk — suitable candidates for cytoreductive surgery as the first step in management.

When first-line treatment did not achieve its goal

First-line management for this population involves upfront (primary) cytoreductive debulking surgery followed by platinum-doublet chemotherapy, with additional agents considered for eligible patients based on disease stage and molecular profile.

The surgical goal is residual disease 1 cm or less in maximum diameter or thickness — the threshold that defines optimal debulking. When this threshold is not met or disease subsequently recurs, this protocol defines the next treatment step.

Next treatment step

For platinum-sensitive recurrent disease, the approach centres on a platinum-based combination regimen alongside an additional targeted agent, with maintenance therapy an option in patients who respond. The complete regimen, eligibility criteria, and sequencing remain in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1200/JOP.18.00662

National Comprehensive Cancer Network recommends that any woman with suspected epithelial ovarian cancer be evaluated by a gynecologic oncologist, because optimal surgical debulking by a skilled physician is central to the initial management of patients with advanced, stage III or IV disease.

ASCO states that although primary cytoreductive surgery is preferred for patients with a high likelihood of achieving optimal debulking, women with high perioperative risk or a low likelihood of achieving optimal cytoreduction should receive neoadjuvant chemotherapy followed by possible interval surgery.

To date, bevacizumab has been FDA approved for the following uses in epithelial ovarian cancer: in combination with carboplatin plus paclitaxel, followed by bevacizumab single agent for stage III or IV disease after initial surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent epithelial ovarian cancer after no more than two prior chemotherapy regimens; and in combination with carboplatin plus paclitaxel or carboplatin plus gemcitabine, followed by bevacizumab single agent, for platinum-sensitive recurrent epithelial ovarian cancer.

All three drugs are approved for maintenance treatment of recurrence of epithelial ovarian cancer in patients with at least a partial response to platinum-based therapy.

View source ↗